Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.095 USD | +0.78% | +27.63% | -19.19% |
12:25pm | North American Morning Briefing : The "Everything -2- | DJ |
16/05 | Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target | MT |
Business Summary
Number of employees: 234
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 70 | 01/20/01 | |
Allan Reine
DFI | Director of Finance/CFO | 49 | 17/01 |
Chief Operating Officer | 52 | 01/22/01 | |
Jeremy Duffield
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/21/01 |
Ann Lee
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/21/01 |
Mohammed Asmal
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fubao Wang
LAW | General Counsel | - | - |
Karen Brown
LAW | General Counsel | - | - |
Niamh Alix
HRO | Human Resources Officer | - | 01/22/01 |
Carman Alenson
AUD | Comptroller/Controller/Auditor | 58 | 01/21/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 01/21/01 | |
Robert Nelsen
BRD | Director/Board Member | 60 | 01/20/01 |
Michael Kelly
BRD | Director/Board Member | 67 | 01/21/01 |
David Schenkein
BRD | Director/Board Member | 66 | 13/19/13 |
Chief Executive Officer | 70 | 01/20/01 | |
Director/Board Member | 46 | 10/23/10 | |
Thomas Cahill
BRD | Director/Board Member | 37 | 01/21/01 |
Wendy Chung
BRD | Director/Board Member | 55 | 01/21/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 120,030,813 | 88,249,113 ( 73.52 %) | 0 | 73.52 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.19% | 81Cr | |
+9.10% | 11TCr | |
+11.46% | 10TCr | |
-12.66% | 2.24TCr | |
-1.05% | 2.23TCr | |
-5.29% | 1.91TCr | |
-38.29% | 1.8TCr | |
-2.93% | 1.79TCr | |
+8.27% | 1.43TCr | |
+34.99% | 1.25TCr |
- Stock Market
- Equities
- PRME Stock
- Company Prime Medicine, Inc.